MA28035A1 - Vaccin - Google Patents
VaccinInfo
- Publication number
- MA28035A1 MA28035A1 MA28868A MA28868A MA28035A1 MA 28035 A1 MA28035 A1 MA 28035A1 MA 28868 A MA28868 A MA 28868A MA 28868 A MA28868 A MA 28868A MA 28035 A1 MA28035 A1 MA 28035A1
- Authority
- MA
- Morocco
- Prior art keywords
- rotavirus
- vaccine
- serotype
- inducing
- patient
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 241000702670 Rotavirus Species 0.000 abstract 1
- 206010067470 Rotavirus infection Diseases 0.000 abstract 1
- 229940124859 Rotavirus vaccine Drugs 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un procédé qui permet d'induire une réponse immunitaire contre une infection par un rotavirus provenant d'un sérotype du rotavirus. Ledit procédé consiste à administrer au patient une composition renfermant un vaccin de rotavirus atténué d'un sérotype différent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49943003P | 2003-09-02 | 2003-09-02 | |
| GBGB0414787.2A GB0414787D0 (en) | 2004-07-01 | 2004-07-01 | Method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28035A1 true MA28035A1 (fr) | 2006-07-03 |
Family
ID=34276843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28868A MA28035A1 (fr) | 2003-09-02 | 2006-03-10 | Vaccin |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP2272532B1 (fr) |
| JP (1) | JP5588586B2 (fr) |
| KR (1) | KR20060126917A (fr) |
| AU (1) | AU2004268375B2 (fr) |
| BR (1) | BRPI0414073A (fr) |
| CA (1) | CA2536734C (fr) |
| HR (2) | HRP20130407T1 (fr) |
| IL (1) | IL173921A0 (fr) |
| IS (1) | IS2922B (fr) |
| MA (1) | MA28035A1 (fr) |
| MX (1) | MXPA06002459A (fr) |
| NO (1) | NO342397B1 (fr) |
| NZ (1) | NZ545639A (fr) |
| PL (2) | PL1660123T3 (fr) |
| RU (1) | RU2368392C2 (fr) |
| SG (1) | SG147465A1 (fr) |
| WO (1) | WO2005021033A2 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5519934B2 (ja) * | 2005-08-17 | 2014-06-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 異型交差防御を誘導するロタウイルスワクチン |
| WO2007081447A2 (fr) | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Antigènes de norovirus et de sapovirus |
| EP2566958B1 (fr) * | 2010-05-03 | 2015-12-30 | GlaxoSmithKline Biologicals S.A. | Procédé pour l'inactivation du virus de la grippe |
| CA2819236A1 (fr) * | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Formulations de virus lyophilisees |
| MX373096B (es) | 2010-12-02 | 2020-04-27 | Oncolytics Biotech Inc | Formulaciones virales líquidas. |
| EP3359651A1 (fr) | 2015-10-05 | 2018-08-15 | THE UNITED STATES OF AMERICA, represented by the S | Souche de rotavirus humain g9p[6]et utilisation comme vaccin |
| US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| AU2018422759B2 (en) * | 2018-05-07 | 2026-01-22 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| CA3224156A1 (fr) | 2021-06-28 | 2023-01-05 | VST LLC dba Medgene Labs | Vaccins contre les sapovirus |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| JP2849632B2 (ja) | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
| WO1992008786A1 (fr) * | 1990-11-16 | 1992-05-29 | James N. Gamble Institute Of Medical Research | Rotavirus humains, vaccins et procedes |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| DE69313134T2 (de) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| US6019982A (en) | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
| EP0988053A1 (fr) | 1997-06-11 | 2000-03-29 | Aquila Biopharmaceuticals, Inc. | Saponines purifiees servant d'adjuvants oraux |
| SK287261B6 (sk) * | 1999-08-17 | 2010-04-07 | Smithkline Beecham Biologicals S.A. | Oslabená ľudská rotavírusová populácia, spôsob jej výroby, vakcínový prostriedok s jej obsahom a jej použitie |
-
2004
- 2004-08-31 MX MXPA06002459A patent/MXPA06002459A/es active IP Right Grant
- 2004-08-31 EP EP10176849.7A patent/EP2272532B1/fr not_active Expired - Lifetime
- 2004-08-31 PL PL04764688T patent/PL1660123T3/pl unknown
- 2004-08-31 EP EP04764688A patent/EP1660123B1/fr not_active Expired - Lifetime
- 2004-08-31 NZ NZ545639A patent/NZ545639A/en unknown
- 2004-08-31 WO PCT/EP2004/009725 patent/WO2005021033A2/fr not_active Ceased
- 2004-08-31 RU RU2006106427/13A patent/RU2368392C2/ru not_active IP Right Cessation
- 2004-08-31 HR HRP20130407TT patent/HRP20130407T1/hr unknown
- 2004-08-31 JP JP2006525097A patent/JP5588586B2/ja not_active Expired - Lifetime
- 2004-08-31 CA CA2536734A patent/CA2536734C/fr not_active Expired - Lifetime
- 2004-08-31 BR BRPI0414073-7A patent/BRPI0414073A/pt not_active Application Discontinuation
- 2004-08-31 AU AU2004268375A patent/AU2004268375B2/en not_active Ceased
- 2004-08-31 KR KR1020067004369A patent/KR20060126917A/ko not_active Ceased
- 2004-08-31 SG SG200807883-4A patent/SG147465A1/en unknown
- 2004-08-31 PL PL10176849T patent/PL2272532T3/pl unknown
-
2006
- 2006-02-23 IL IL173921A patent/IL173921A0/en unknown
- 2006-02-23 IS IS8325A patent/IS2922B/is unknown
- 2006-02-28 NO NO20060976A patent/NO342397B1/no unknown
- 2006-03-10 MA MA28868A patent/MA28035A1/fr unknown
-
2016
- 2016-03-23 HR HRP20160299TT patent/HRP20160299T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IS2922B (is) | 2015-04-15 |
| SG147465A1 (en) | 2008-11-28 |
| CA2536734C (fr) | 2014-07-08 |
| HRP20130407T1 (en) | 2013-06-30 |
| EP2272532A2 (fr) | 2011-01-12 |
| IS8325A (is) | 2006-02-23 |
| KR20060126917A (ko) | 2006-12-11 |
| JP2007516215A (ja) | 2007-06-21 |
| HRP20160299T1 (hr) | 2016-04-22 |
| PL1660123T3 (pl) | 2013-08-30 |
| EP2272532B1 (fr) | 2016-02-10 |
| PL2272532T3 (pl) | 2016-07-29 |
| EP1660123A2 (fr) | 2006-05-31 |
| WO2005021033A2 (fr) | 2005-03-10 |
| MXPA06002459A (es) | 2006-06-20 |
| NO20060976L (no) | 2006-03-31 |
| RU2368392C2 (ru) | 2009-09-27 |
| IL173921A0 (en) | 2006-07-05 |
| RU2006106427A (ru) | 2007-10-10 |
| AU2004268375B2 (en) | 2010-01-28 |
| BRPI0414073A (pt) | 2006-10-24 |
| EP1660123B1 (fr) | 2013-03-13 |
| EP2272532A3 (fr) | 2012-08-01 |
| AU2004268375A1 (en) | 2005-03-10 |
| NZ545639A (en) | 2009-04-30 |
| JP5588586B2 (ja) | 2014-09-10 |
| CA2536734A1 (fr) | 2005-03-10 |
| WO2005021033A3 (fr) | 2005-05-06 |
| NO342397B1 (no) | 2018-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107146T1 (el) | Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad) | |
| DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
| MA30866B1 (fr) | Vaccin | |
| ATE419872T1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
| WO2005097211A3 (fr) | Compositions adjuvantes ameliorant la reponse immunitaire a des vaccins et methodes d'utilisation | |
| NO20010922D0 (no) | FremgangsmÕte for DNA vaksinering | |
| HUP0303720A2 (hu) | Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény | |
| ATE426412T1 (de) | Adjuvante influenza-vakzine | |
| CY1106357T1 (el) | Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων | |
| TR200103574T2 (tr) | Amid ikameli/katkılı imidazokinolinler | |
| HRP20041152B1 (hr) | Farmaceutske formulacije | |
| NO20076239L (no) | Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom | |
| EA200970013A1 (ru) | Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы | |
| MA29601B1 (fr) | Vaccin antipaludeen | |
| BRPI0510430A (pt) | composições e métodos para vacinação mucosal | |
| MA32030B1 (fr) | Vaccins anti-malaria | |
| EP1385541A4 (fr) | Compositions immunostimulantes comprenant un phosphate d'aminoalkyl glucosaminide et du qs-21 | |
| EA200600403A1 (ru) | Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки | |
| DE60331412D1 (de) | Hiv-vakzine und anwendungsverfahren | |
| MA29133B1 (fr) | Nouvelle combinaison | |
| ATE310008T1 (de) | Immunologische adjuvans verbindungen | |
| CY1116135T1 (el) | Εμβολιο ροταϊου που διεγειρει ετεροτυπικη εγκαρσια προστασια | |
| SG147465A1 (en) | Vaccine | |
| WO2003103570A3 (fr) | Immunisation transcutanee contre le papillomavirus avec un virus de type papillomavirus | |
| EP1841451A4 (fr) | Peptides destinés à l'administration de vaccins muqueux |